PATENT COOPERATION TREATY







INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

(Chapter II of the Patent Cooperation Treaty)

(PCT Article 36 and Rule 70)

Applicant's or agent's file reference PU0265	FOR FURTHER ACTION See Fo	THER ACTION See Form PCT/IPEA/416	
International application No.	International filing date (day/month/year)	Priority date (day/month/year)	
PCT/SE2003/001016	17.06.2003	27.08.2002	
International Patent Classification (IPC) or	national classification and IPC		
C12N 15/10	·	·	
Applicant			
Amersham Biosciences A	AB et al		
	liminary examination report, established by insmitted to the applicant according to Art	y this International Preliminary Examining icle 36.	
2. This REPORT consists of a total o	,,		
This report is also accompanied by	ANNEXES, comprising:		
a. (sent to the applicant of	and to the International Bureau) a total of	sheets, as follows:	
1		have been amended and are the basis of this report	
and/or sheets of		Authority (see Rule 70.16 and Section 607 of the	
		thority considers contain an amendment that goes	
Supplemental		filed, as indicated in item 4 of Box No. I and the	
b. (sent to the Internation	nal Bureau only) a total of (indicate type a	nd number of electronic carrier(s))	
		ing and/or tables related thereto, in computer	
readable form only, as Administrative Instruc		ng to Sequence Listing (see Section 802 of the	
4. This report contains indications rel	lating to the following items:		
Box No. I Basis of	the report	•	
Box No. II Priority		•	
Box No. III Non-esta	ablishment of opinion with regard to novel	ty, inventive step and industrial applicability	
Box No. IV Lack of	unity of invention		
Box No. V Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement			
Box No. VI Certain documents cited			
Box No. VII Certain o	Box No. VII Certain defects in the international application		
Box No. VIII Certain			
Date of submission of the demand Date of completion of this report			
18.03.2004	5 11 200	5.11.2004	
Name and mailing address of the IPEA/SE		Authorized officer	
Patent- och registreringsverket			
Box 5055 S-102 42 STOCKHOLM Terese Persson/EÖ			
Facsimile No. +46 8 667 72 88	+46 8 782 25 00		

Form PCT/IPEA/409 (cover sheet) (January 2004)

INTERNATIONAL PREIMARY REPORT ON PATENTABILITY

International	application No.
PCT/S	03/001016

Box	No. 1	Basis of the report
1.		regard to the language, this report is based on the international application in the language in which it was filed, unless vise indicated under this item.
		This report is based on a translation from the original language into the following language which is the language of a translation furnished for the purposes of:
		international search (under Rules 12.3 and 23.1(b))
		publication of the international application (under Rule 12.4)
		international preliminary examination (under Rules 55.2 and/or 55.3)
2.	furnisi	regard to the elements of the international application, this report is based on (replacement sheets which have been hed to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" re not annexed to this report):
	\boxtimes	the international application as originally filed/furnished
		the description:
İ		pagesas originally filed/furnished
		pages* received by this Authority on
		pages* received by this Authority on
		the claims:
		pages as originally filed/furnished
		pages* as amended (together with any statement) under Article 19 pages* received by this Authority on
Ì		pages* received by this Authority on
	\Box	the drawings:
		pages as originally filed/furnished
		pages* received by this Authority on
		pages* received by this Authority on
		a sequence listing and/or any related table(s) - see Supplemental Box Relating to Sequence Listing.
3.		The amendments have resulted in the cancellation of:
		the description, pages
		the claims. Nos
		the sequence listing (specify):
		any table(s) related to the sequence listing (specify):
4.		This report has been established as if (some of) the amendments annexed to this report and listed below had not been made, since they have been considered to go beyond the disclosure as filed, as indicated in the Supplemental Box (Rule 70.2(c)).
		the description, pages
		the claims, Nos.
		the drawings, sheets/figs
		the sequence listing (specify):
		any table(s) related to the sequence listing (specify):
*	If item	4 applies, some or all of those sheets may be marked "superseded."
Form	PCT/II	PEA/409 (Box No. I) (January 2004)
. 5.11		(() (valual) *vv)

INTERNATIONAL PREI

International application No.	
PCT/S 03/001016	

Box No. III Non-establishment of opinion with regard to novelty, inventive step and industrial applicability		
The questions whether the claimed invention appears to be novel, to involve an inventive step (to be non obvious), or to be industrially applicable have not been examined in respect of:		
	the entire international application	
\boxtimes	claims Nos. 11-13 (partially)	
becau	use:	
	the said international application, or the said claims Nos. relate to the following subject matter which does not require an international preliminary examination (specify):	
1	·	
·	<u> </u>	
Ш	the description, claims or drawings (indicate particular elements below) or said claims Nos. are so unclear that no meaningful opinion could be formed (specify):	
	the claims, or said claims Nos. are so inadequately supported by the description that no meaningful opinion could be formed.	
	the nucleotide and/or amino acid sequence listing does not comply with the standard provided for in Annex C of the Administrative Instructions in that:	
	the written form has not been furnished	
	does not comply with the standard	
	the computer readable form has not been furnished	
	does not comply with the standard the tables related to the nucleotide and/or amino acid sequence listing, if in computer readable form only, do not comply with	
	the technical requirements provided for in the Annex C-bis of the Administrative Instructions.	
	See Supplemental Box for further details.	

Form PCT/IPEA/409 (Box No. 111) (January 2004)

Box No. V	Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability;
	citations and explanations supporting such statement

1.	Statement

Novelty (N)	Claims	1-10,14-21	YES
	Claims	11-13	NO
Inventive step (IS)	Claims	1÷10,14-21	YES.
	Claims	11-13	NO
Industrial applicability (IA)	Claims	1-21	YES
	Claims		NO

2. Citations and explanations (Rule 70.7)

Documents cited in the International Search Report:

D1: WO 9811140 A1

D2: Journal of Chromatography A, Volume 864, 1999, Josefine Persson et al: "Purification of protein and recycling of polymers in a new aqueous two-phase system using two thermoseparating polymers", pages 31-48

D3: International Symposium on Separations for Biotechnology Reading: Separation for biotechnology 3. Cambridge: royal Society of Chemistry, 1994, Folke Tjerneld et al: "Utilization of Temperature-induced Phase Separation for Purification of Biomolecules", pages 505-511

D4: Biotechnology and Bioengineering, Volume 78, no. 4, 20 May 2002, S.C. Ribiero et al: "Isolation of Plasmid DNA from Cell Lysates by Aqueous Two-Phase Systems", pages 376-384

D1 discloses different composition, among others, a composition comprising Reppal PES 200, a hydroxypropyl starch, and UCON 50-HB-5100, a copolymer of ethylene oxide and propylene oxide with a cloud point of 50°C. Reppal PES 200 is preferably used in a concentration of 1-30 % (w/w) and UCON 50-HB-5100 is preferably used in a concentration of 0.5-30 % (w/w). (Page 10, lines 7-16; page 12, lines 25-28; page 14, lines 18-19; the claims.)

D2-D3 disclose similar compositions comprising a first polymer that exhibits inverse solubility characteristics at temperatures below about 60°C and a second polymer that is immiscible in the first polymer.

D2 discloses a composition comprising EO50PO50 and HM-EOPO and D3 discloses a composition comprising Ucon in combination with dextran. (D2: figure 4; D3: page 506, paragraph 2.)

INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

International application No.

PCT/S

03/001016

Supplemental Box

In case the space in any of the preceding boxes is not sufficient. Continuation of: Box V

The present claims 11-13 relate to a composition, such as the one described in D1, for extraction of plasmid DNA. However, the scope of claims 11-13 covers the composition per se, regardless of what it is used for. Consequently, the subject matter claimed in claims 11-13 lacks novelty.

To summaries, the subject matter claimed in claims 11-13 lacks novelty. The subject matter claimed in claims 1-10 and 14-21 is novel and is considered to involve an inventive step. The subject matter claimed in claims 1-21 is considered to be industrially applicable.

International application No.
PCT/S 03/001016

Box No. VIII Certain observations on the international application

The following observations on the claims of the claims, description, and drawings or on the question whether the claims are fully supported by the description, are made:

Claims 11-13 relate to compositions comprising a first and a second polymer each having particular properties, namely, the first polymer should exhibit inverse solubility characteristics below about 60°C and the second polymer should be immiscible in the first polymer. The claims cover all compositions having such polymers, whereas the description supports only a limited number of compositions. It is considered impossible to compare the parameters of the claims with known compositions. These parameters are considered to render the scope of the claims unclear, see PCT art 5 and 6.

Wordings such as "about" is considered to lead to a lack of clarity. Consequently, the wording of claims 2, 4, 6, 7, 11, 14, 17 and 20 is considered to render the scope of the claims unclear and thus, the claims are considered to not fulfil the requirements of PCT Art 6.